Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    02760485
Previous Study | Return to List | Next Study

A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02760485
Recruitment Status : Active, not recruiting
First Posted : May 3, 2016
Last Update Posted : November 15, 2021
Sponsor:
Information provided by (Responsible Party):
Incyte Corporation

Brief Summary:
The purpose of this study is to evaluate the safety/tolerability and efficacy of itacitinib in combination with ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Condition or disease Intervention/treatment Phase
Lymphoma Drug: itacitinib Drug: ibrutinib Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Phase 1/2 Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Actual Study Start Date : December 29, 2016
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
Drug Information available for: Ibrutinib

Arm Intervention/treatment
Experimental: itacitinib + ibrutinib Drug: itacitinib
Phase 1 will evaluate itacitinib at the protocol-specified starting dose, with a possible increase or decrease depending on tolerability. Phase 2 will evaluate the recommended dose determined in Phase 1.
Other Name: INCB039110

Drug: ibrutinib



Primary Outcome Measures :
  1. Phase 1: Safety and tolerability as assessed by adverse events and changes in clinical and laboratory assessments [ Time Frame: Screening through 35 days after end of treatment, estimated to be 12 months ]
  2. Phase 2: Efficacy as assessed by objective response rate (ORR) [ Time Frame: Weeks 8, 16, and every 16 weeks thereafter, estimated to be 12 months ]
    Defined as percentage of subjects achieving a complete response (CR) or partial response (PR) based on radiographic assessment.


Secondary Outcome Measures :
  1. Phase 1: Efficacy as assessed by objective response rate (ORR) [ Time Frame: Screening through 16 weeks ]
    Defined as percentage of subjects achieving a complete response (CR) or partial response (PR) based on radiographic assessment.

  2. Phase 2: Efficacy as assessed by duration of response (DOR) [ Time Frame: Weeks 8, 16, and every 16 weeks thereafter, estimated to be 12 months ]
    Defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.

  3. Phase 2: Durable response rate [ Time Frame: Screening through 16 weeks ]
    Durable response rate is defined as the percentage of subjects achieving a CR or PR for > 16 weeks.

  4. Phase 2: Efficacy as assessed by progression-free survival (PFS) [ Time Frame: Weeks 8, 16, and every 16 weeks thereafter, estimated to be 12 months ]
    Defined as date of enrollment to earliest date of disease progression based on radiographic assessment or death due to any cause.

  5. Phase 2: Efficacy as assessed by overall survival (OS) [ Time Frame: Every 12 weeks, estimated to be 12 months ]
    Defined as date of enrollment until death due to any cause.

  6. Phase 2: Number of treatment-emergent adverse events [ Time Frame: Screening through 35 days after end of treatment, estimated to be 12 months ]
    Any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically documented diagnosis of DLBCL.

    • Phase 1: any DLBCL subtype.
    • Phase 2: activated B-cell or unclassifiable subtypes confirmed by immunohistochemistry using the Hans algorithm
  • Relapsed or refractory DLBCL, defined as having received at least 1 but no more than 3 prior treatment regimens and ineligible for high-dose chemotherapy/autologous stem cell transplant.
  • Fluorodeoxyglucose-avid disease (based on local evaluation) per the Lugano Classification. Fluorodeoxyglucose-avid disease is defined as disease with a 5-point scale score of 4 or 5.
  • Archived tumor tissue (block or 15-20 unstained slides) available, or be willing to undergo an incisional or excisional lymph node biopsy of accessible adenopathy (or, in less accessible lymph nodes, 4 to 8 core biopsies).
  • At least 1 measurable (≥ 2 cm in longest dimension) lesion on CT scan or magnetic resonance imaging (MRI).
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

Exclusion Criteria:

  • Transformed DLBCL or DLBCL with coexistent histologies (eg, follicular or mucosa-associated lymphoid tissue lymphoma).
  • Primary mediastinal (thymic) large B-cell lymphoma.
  • Known central nervous system lymphoma (either primary or metastatic).
  • Allogeneic stem cell transplant within the previous 6 months, or active graft versus host disease following allogeneic transplant.
  • Use of immunosuppressive therapy within 28 days of starting study treatment. Immunosuppressive therapy includes but is not limited to cyclosporine A, tacrolimus, or high-dose corticosteroids. Subjects receiving corticosteroids must be at a dose level ≤ 10 mg/day within 7 days of initiating study treatment.
  • Prior or concurrent therapy with a Janus kinase inhibitor or Bruton's tyrosine kinase inhibitor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02760485


Locations
Show Show 21 study locations
Sponsors and Collaborators
Incyte Corporation
Investigators
Layout table for investigator information
Study Director: Fitzroy Dawkins, MD Incyte Corporation
Layout table for additonal information
Responsible Party: Incyte Corporation
ClinicalTrials.gov Identifier: NCT02760485    
Other Study ID Numbers: INCB 39110-206
First Posted: May 3, 2016    Key Record Dates
Last Update Posted: November 15, 2021
Last Verified: November 2021
Keywords provided by Incyte Corporation:
Diffuse large B-cell lymphoma
Relapsed Diffuse large B-cell lymphoma
Refractory Diffuse large B-cell lymphoma
activated B cell
germinal center B-cell
non-Hodgkin lymphoma
JAK1 inhibitor
Bruton's tyrosine kinase (BTK) inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin